{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:55:41Z","timestamp":1792112141525,"version":"4.4.0"},"reference-count":5,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj-2026-100896","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:35:16Z","timestamp":1789655716000},"page":"e100896","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Breast cancer: Life extending drug is now available on NHS in England"],"prefix":"10.1136","volume":"394","author":[{"given":"Matthew","family":"Limb","sequence":"first","affiliation":[{"name":"London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026091711251429000_394.sep17_10.e100896.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q2620"},{"key":"2026091711251429000_394.sep17_10.e100896.2","unstructured":"National Institute for Health and Care Excellence. NICE recommends Enhertu for people with HER2-low advanced breast cancer. 17 Sep 2026. https:\/\/www.nice.org.uk\/news\/articles\/nice-recommends-enhertu-for-people-with-her2-low-advanced-breast-cancer"},{"key":"2026091711251429000_394.sep17_10.e100896.3","unstructured":"National Institute for Health and Care Excellence. Changes to NICE\u2019s cost-effectiveness thresholds confirmed. 1 Dec 2025. https:\/\/www.nice.org.uk\/news\/articles\/changes-to-nice-s-cost-effectiveness-thresholds-confirmed"},{"key":"2026091711251429000_394.sep17_10.e100896.4","unstructured":"National Institute for Health and Care Excellence. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy: final draft guidance. https:\/\/www.nice.org.uk\/guidance\/gid-ta12551\/documents\/674"},{"key":"2026091711251429000_394.sep17_10.e100896.5","unstructured":"Scottish Medicines Consortium. SMC approves trastuzumab deruxtecan (Enhertu) for use on NHS in Scotland. Dec 2023. https:\/\/breastcancernow.org\/about-us\/media\/statements\/scottish-medicines-consortium-smc-approves-trastuzumab-deruxtecan-enhertu-for-use-on-nhs-in-scotland"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2026-100896","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2026-100896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:25:22Z","timestamp":1789669522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2026-100896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":5,"alternative-id":["10.1136\/bmj-2026-100896"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2026-100896","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}